Ocugen Files 8-K Report
Ticker: OCGN · Form: 8-K · Filed: Mar 18, 2024 · CIK: 1372299
| Field | Detail |
|---|---|
| Company | Ocugen, INC. (OCGN) |
| Form Type | 8-K |
| Filed Date | Mar 18, 2024 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.01 |
| Sentiment | neutral |
Sentiment: neutral
Topics: 8-K, regulatory-filing
TL;DR
Ocugen filed a standard 8-K, no major news but check financials.
AI Summary
Ocugen, Inc. filed an 8-K on March 18, 2024, to report on other events and financial statements. The filing includes information about the company's operations and financial condition, but does not detail specific new developments or transactions.
Why It Matters
This 8-K filing provides routine updates on Ocugen's corporate and financial status, which is important for investors to monitor the company's ongoing activities.
Risk Assessment
Risk Level: low — This filing is a routine 8-K report and does not appear to contain any significant new risks or material adverse information.
Key Players & Entities
- Ocugen, Inc. (company) — Registrant
- March 18, 2024 (date) — Date of Report
- Delaware (jurisdiction) — State of Incorporation
- 11 Great Valley Parkway Malvern, Pennsylvania 19355 (address) — Principal Executive Office
- 484-328-4701 (phone_number) — Principal Executive Office Telephone
FAQ
What is the primary purpose of this 8-K filing for Ocugen, Inc.?
The primary purpose of this 8-K filing is to report on 'Other Events' and 'Financial Statements and Exhibits' as of March 18, 2024.
What is Ocugen, Inc.'s state of incorporation?
Ocugen, Inc. is incorporated in Delaware.
What is the principal executive office address for Ocugen, Inc.?
The principal executive office is located at 11 Great Valley Parkway, Malvern, Pennsylvania 19355.
What is the telephone number for Ocugen, Inc.'s principal executive office?
The telephone number is (484) 328-4701.
What is the SEC file number for Ocugen, Inc.?
The SEC file number for Ocugen, Inc. is 001-36751.
Filing Stats: 528 words · 2 min read · ~2 pages · Grade level 10.1 · Accepted 2024-03-18 08:54:16
Key Financial Figures
- $0.01 — nge on which registered Common Stock, $0.01 par value per share OCGN The Nasdaq
Filing Documents
- tm249080d1_8k.htm (8-K) — 27KB
- tm249080d1_ex99-1.htm (EX-99.1) — 12KB
- tm249080d1_ex99-1img001.jpg (GRAPHIC) — 3KB
- 0001104659-24-035293.txt ( ) — 214KB
- ocgn-20240318.xsd (EX-101.SCH) — 3KB
- ocgn-20240318_lab.xml (EX-101.LAB) — 33KB
- ocgn-20240318_pre.xml (EX-101.PRE) — 22KB
- tm249080d1_8k_htm.xml (XML) — 3KB
01 Other Events
Item 8.01 Other Events. On March 18, 2024, Ocugen announced the Qamar Appointment. Item 9.01 Financial Statements and Exhibits. The following exhibits are being furnished herewith: (d) Exhibits Exhibit No. Document 99.1 Ocugen, Inc. Press Release dated March 18, 2024. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document). SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: March 18, 2024 OCUGEN, INC. By: /s/ Shankar Musunuri Name: Shankar Musunuri Title: Chairman, Chief Executive Officer, & Co-Founder